Published on 26/12/2025
Why Missing Safety Narratives Remain a Major Regulatory Audit Concern
Introduction: The Role of Safety Narratives
Safety narratives are integral components of pharmacovigilance reporting, providing a detailed description of individual Serious Adverse Events (SAEs) or Suspected Unexpected Serious Adverse Reactions (SUSARs). They include clinical context, chronology, medical assessments, and outcomes, enabling regulators to evaluate causality and risk.
Regulatory agencies such as the FDA, EMA, and MHRA expect sponsors to provide comprehensive narratives as part of expedited reporting, Development Safety Update Reports (DSURs), and final Clinical Study Reports (CSRs). Missing or incomplete safety narratives are among the most common audit findings, often categorized as major deficiencies because they compromise the ability of regulators to assess drug safety accurately.
Regulatory Expectations for Safety Narratives
According to ICH E2A and ICH E3 guidelines, narratives should provide:
- A clear chronological account of the adverse event.
- Patient demographics and baseline medical history.
- Details of the investigational product, dosing, and exposure.
- Clinical course, investigations, treatments, and outcomes.
- Sponsor and investigator causality assessments.
Common Audit Findings on Missing Safety Narratives
1. Absent Narratives in DSURs
Auditors often identify DSURs that include cumulative safety data but omit narratives for key SAEs or SUSARs. This is considered a major compliance gap.
2. Incomplete Narratives
Some narratives lack important clinical details, such as laboratory results, diagnostic imaging, or outcome documentation. Such omissions weaken the scientific value of the report.
3. Delayed Narrative Updates
Follow-up data is sometimes missing from safety narratives, leaving the case incomplete at the time of submission.
4. CRO Oversight Failures
When CROs prepare narratives, sponsors sometimes fail to verify completeness, resulting in missing or inconsistent data across submissions.
Case Study: EMA Audit Findings on Missing Narratives
In a Phase III immunology trial, EMA inspectors found that 10 SUSARs were reported without narratives, while another 15 had incomplete medical details. The deficiency was classified as critical because it prevented regulators from conducting a full causality assessment. The sponsor was required to resubmit corrected narratives, retrain staff, and implement a narrative quality review process.
Root Causes of Missing Safety Narratives
Audit investigations frequently identify the following systemic root causes:
- Lack of standardized templates for narrative preparation.
- Inadequate training of pharmacovigilance and medical writing teams.
- Over-reliance on CROs without strong sponsor oversight.
- Time pressures leading to submission of incomplete narratives.
- Poor integration between clinical and pharmacovigilance databases.
Corrective and Preventive Actions (CAPA)
Corrective Actions
- Resubmit missing narratives for all incomplete SAE/SUSAR cases.
- Update pharmacovigilance safety databases with full narrative details.
- Audit CRO-prepared narratives and enforce corrective measures.
Preventive Actions
- Develop standardized narrative templates to ensure completeness and consistency.
- Train safety and medical writing staff on narrative requirements and best practices.
- Integrate narrative preparation into case management workflows with quality control steps.
- Conduct quarterly audits of safety narratives within DSURs and CSRs.
Sample Safety Narrative Template
The following dummy structure illustrates a standardized narrative template for SAE reporting:
| Section | Details Required |
|---|---|
| Patient Demographics | Age, sex, relevant medical history |
| Drug Exposure | Investigational product, dose, duration |
| Event Description | Chronology, onset date, symptoms, severity |
| Investigations | Lab results, imaging, other diagnostics |
| Treatment and Outcome | Therapies administered, recovery or fatal outcome |
| Causality Assessment | Investigator and sponsor evaluations |
Best Practices for Safety Narratives
To ensure audit readiness and compliance, sponsors and CROs should follow these best practices:
- Use standardized templates across global clinical trials.
- Perform cross-functional reviews of narratives before submission.
- Reconcile safety narratives with CRFs, EDC, and pharmacovigilance databases.
- Ensure DSURs and CSRs include narratives for all SAEs and SUSARs.
- Establish KPIs to monitor CRO performance in narrative preparation.
Conclusion: Building Stronger Safety Narrative Compliance
Missing or incomplete safety narratives are recurring audit findings with significant regulatory consequences. These deficiencies compromise causality assessments, delay regulatory decision-making, and undermine sponsor credibility.
Sponsors can mitigate these risks by adopting standardized templates, ensuring strong CRO oversight, and integrating narratives into case workflows. Complete, timely, and accurate safety narratives not only satisfy regulatory requirements but also demonstrate a sponsor’s commitment to patient safety.
For additional guidance, see the ANZCTR Clinical Trials Registry, which emphasizes the importance of transparent and complete safety reporting.